Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (prostatic glandular cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: omarigliptin, vildagliptin, trelagliptin succinate +18 | 1.00 |
| trials ClinicalTrials.gov | 3 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 56 Parkinson's papers of 6,882 | 0.47 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2683
Sealed predictions
- DPP4 in dopamine neurons, braak+0.01 (p 0.982) → +0.48 (p 0.187)receipt 2691
Swarm cases
receipt 2691: DPP4 in dopamine neurons, braak
- power
- full sample +0.10 (p 0.696, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.11 (p 0.671, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.03 (p 0.915, n 18). could be the mix.
- skeptic
- leave-one-out range -0.01 to +0.24, sign flips 1; without severely affected donors +0.10 (p 0.696, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DPP4 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts